BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BrainsGate Closes $27.5M Round Led by Johnson & Johnson Development Corporation, Joined by Agate Medical Investments


8/13/2008 7:43:21 AM

CAESAREA, Israel--(BUSINESS WIRE)--BrainsGate Ltd., a developer of an innovative therapeutic platform technology based on electrical neurostimulation of the Spheno-Palatine Ganglion, today announced the completion of a $27.5M series C financing round in which both new and existing investors participated.

Johnson & Johnson Development Corporation (JJDC) led the round, joined by VC-Fund Agate Medical Investments LP, headed by Israel's former Minister of Health Mr. Danny Naveh. Prominent existing investors who also participated in the current round included Elron Electronic industries (NASDAQ:ELRN - News)(TASE:ELRN), Pitango Venture Capital, MB Venture Capital and Alice Lab.

"This investment, paired with the substantial experience of our new and existing investors, will serve as key driving factors in enabling the company to move ahead in conducting the pivotal clinical study. This study represents a key stage in the Company's progress in gaining market approval for its innovative acute ischemic stroke treatment," commented Avinoam Dayan, CEO of BrainsGate, adding "I would like to welcome our new investors, while thanking our existing shareholders for their ongoing support of the Company."

About BrainsGate

BrainsGate is a developer of a novel therapeutic platform based on electrical neurostimulation of the Spheno-Palatine Ganglion (SPG). BriansGate's leading indication is acute ischemic stroke with a 24 hour treatment window. The company is nearing completion of a multi-national multi-center pilot clinical study which to date has recruited over 90 stroke patients, and is about to initiate a pivotal study to gain market approval for its stroke therapy.

For more information please visit www.brainsgate.com.

Contact:

BrainsGate Ltd. Raveh Gill-More +972-4-637-7774 raveh@brainsgate.com

Source: Elron Electronic Industries

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES